LIFEVANTAGE CORP Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent
LIFEVANTAGE CORP (LFVN) reported Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent of 0.00% for the 12-month period ending 2020-06-30, per its 10-K filed 2020-08-18.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities · last filed 2020-08-18
- LIFEVANTAGE CORP effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2020 was 0.00%.
- LIFEVANTAGE CORP effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2019 was 0.00%, a 100.00% decline from fiscal 2018.
- LIFEVANTAGE CORP effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2018 was 1.50%, a 54.55% decline from fiscal 2017.
- LIFEVANTAGE CORP effective income tax rate reconciliation, deduction, qualified production activity, percent for fiscal 2017 was 3.30%, a 25.00% decline from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent 12 month | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent 12 month as first filed |
|---|---|---|
| 2020-06-30 | 0.00% 10-K · filed 2020-08-18 | |
| 2019-06-30 | 0.00% 10-K · filed 2020-08-18 | |
| 2018-06-30 | 1.50% 10-K · filed 2020-08-18 | |
| 2017-06-30 | 3.30% 10-K · filed 2019-08-14 | |
| 2016-06-30 | 4.40% 10-K · filed 2018-08-15 | |
| 2015-06-30 | 1.60% 10-K · filed 2017-09-07 | |
| 2014-06-30 | 1.80% 10-K · filed 2016-12-12 | |
| 2013-06-30 | 2.70% 10-K · filed 2015-09-01 | 2.73% 10-K · filed 2013-09-12 |
| 2012-06-30 | 0.00% 10-K · filed 2014-09-10 | |
| 2011-06-30 | 0.00% 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |